Iridex Corp (IRIX) — SEC Filings
Iridex Corp (IRIX) — 30 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 19 8-K, 5 10-Q, 2 DEFA14A.
Overview
Iridex Corp (IRIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: IRIDEX CORP reported a net loss of $1.573 million for the three months ended September 27, 2025, an improvement from the $1.933 million net loss in the prior-year period. For the nine months, the net loss significantly decreased to $4.253 million from $8.076 million year-over-year. Total revenues in
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 3 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Iridex Corp is neutral.
Filing Type Overview
Iridex Corp (IRIX) has filed 19 8-K, 5 10-Q, 2 DEFA14A, 1 DEF 14A, 2 10-K, 1 8-K/A with the SEC between Mar 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of IRIX's 29 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $37.951M |
| Net Income | $(4.253)M |
| EPS | N/A |
| Debt-to-Equity | 5.05 |
| Cash Position | $5.573M |
| Operating Margin | -17.0% |
| Total Assets | $30.030M |
| Total Debt | $23.672M |
Key Executives
- David L. Wilson
- Robert J. Dolnik
- David J. L. Wilson
- Dr. David S. Bear
- Mr. Robert L. W. Smith
- Michael J. McCurdy
- Dr. David S. Chen
- Mr. David J. Reiss
- Mr. Elias N. Efthimiatos
Industry Context
IRIDEX CORP operates in the highly competitive medical technology sector, specifically focusing on ophthalmic devices. The industry is characterized by rapid innovation, stringent regulatory oversight (FDA, international bodies), and a need for significant R&D investment. Companies like IRIDEX must navigate complex reimbursement landscapes and demonstrate clinical efficacy to gain market adoption against established players and agile startups.
Top Tags
sec-filing (5) · financials (5) · corporate-governance (4) · compensation (3) · proxy-statement (3) · 10-Q (3) · Medical Devices (2) · 8-K (2) · filing (2) · exhibits (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues (3 months) | $12.484M | Increased from $11.581M in prior year, showing growth. |
| Total Revenues (9 months) | $37.951M | Increased from $35.973M in prior year, indicating sustained revenue growth. |
| Net Loss (3 months) | $(1.573)M | Improved from $(1.933)M in prior year, narrowing losses. |
| Net Loss (9 months) | $(4.253)M | Significantly improved from $(8.076)M in prior year, nearly halving losses. |
| Total Operating Expenses (3 months) | $5.424M | Reduced from $6.193M in prior year, demonstrating cost control. |
| Total Operating Expenses (9 months) | $16.306M | Reduced from $21.716M in prior year, indicating substantial expense management. |
| Cash and Cash Equivalents | $5.573M | Increased from $2.387M at December 28, 2024, boosting liquidity. |
| Proceeds from Series B Preferred Stock | $6.000M | Key financing activity contributing to increased cash. |
| Total Stockholders' Equity | $4.681M | Increased from $2.097M at December 28, 2024, strengthening the balance sheet. |
| Accumulated Deficit | $(92.262)M | Increased from $(88.009)M, indicating continued historical losses. |
| Net Loss | $2.4M | Increased from $1.6M in prior year, indicating worsening profitability. |
| Revenue | $11.5M | Decreased by 5% from $12.1M in prior year, showing sales contraction. |
| Gross Profit Margin | 48.7% | Stable compared to 48.8% in prior year, but not enough to offset other costs. |
| Revenue from Topcon Corporation | 10% | Customer concentration risk, though down from 12% in prior year. |
| Revenue from Netherlands | 20% | Geographic concentration risk for the six months ended June 28, 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Iridex Corp (IRIX)?
Iridex Corp has 30 recent SEC filings from Mar 2024 to Dec 2025, including 19 8-K, 5 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IRIX filings?
Across 30 filings, the sentiment breakdown is: 3 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Iridex Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Iridex Corp (IRIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Iridex Corp?
Key financial highlights from Iridex Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IRIX?
The investment thesis for IRIX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Iridex Corp?
Key executives identified across Iridex Corp's filings include David L. Wilson, Robert J. Dolnik, David J. L. Wilson, Dr. David S. Bear, Mr. Robert L. W. Smith and 4 others.
What are the main risk factors for Iridex Corp stock?
Of IRIX's 29 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Iridex Corp?
Forward guidance and predictions for Iridex Corp are extracted from SEC filings as they are enriched.